Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RAB9A | P51151 | 9/20 | 0.57 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.57 |
| ▸ | MEN1 | O00255 | 3/20 | 0.57 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.46 |
| ▸ | TRPV1 | Q8NER1 | 1/20 | 0.44 |
| ▸ | NPC1 | O15118 | 5/20 | 0.43 |
| ▸ | PKM | P14618 | 2/20 | 0.43 |
| ▸ | MAPT | P10636 | 1/20 | 0.43 |
| ▸ | APOBEC3A | P31941 | 1/20 | 0.43 |
| ▸ | APOBEC3G | Q9HC16 | 1/20 | 0.43 |
| ▸ | L3MBTL1 | Q9Y468 | 3/20 | 0.42 |
| ▸ | LCLAT1 | Q6UWP7 | 1/20 | 0.42 |
| ▸ | TP53 | P04637 | 1/20 | 0.42 |
| ▸ | P4HTM | Q9NXG6 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.41 |
| ▸ | NAMPT | P43490 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL310379 | 0.89 | MEN1 (0.41) | RAB9AKMT2AMEN1SMN1; SMN2NPC1 | |
| SCHEMBL1640321 | 0.84 | MEN1 (0.40) | RAB9AKMT2AMEN1SMN1; SMN2TRPV1 | |
| SCHEMBL1640536 | 0.81 | KCNQ3 (0.45) | RAB9AKMT2AMEN1SMN1; SMN2TRPV1 | |
| SCHEMBL3796539 | 0.78 | RAB9A (0.38) | RAB9ATRPV1NPC1TP53ALDH1A1 | |
| SCHEMBL24760920 | 0.76 | ERCC5 (0.47) | RAB9AKMT2AMEN1SMN1; SMN2NPC1 | |
| SCHEMBL2194305 | 0.76 | SLC40A1 (0.43) | RAB9AKMT2AMEN1SMN1; SMN2NPC1 | |
| SCHEMBL310067 | 0.76 | RAB9A (0.44) | RAB9AKMT2AMEN1SMN1; SMN2NPC1 | |
| SCHEMBL24760727 | 0.76 | RAB9A (0.53) | RAB9AKMT2AMEN1SMN1; SMN2NPC1 | |
| SCHEMBL1640293 | 0.76 | FADS1 (0.45) | RAB9AKMT2AMEN1SMN1; SMN2TRPV1 | |
| SCHEMBL3422489 | 0.75 | NPC1 (0.42) | RAB9AKMT2AMEN1SMN1; SMN2TRPV1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2162454-B1 | IMIDAZOPYRIDINE KINASE INHIBITORS | GLAXOSMITHKLINE LLC (US) | 2013-01-02 | — | — | EP | disclosed |
| US-8093239-B2 | Imidazopyridine kinase inhibitors | GLAXOSMITHKLINE LLC (US) | 2012-01-10 | — | — | US | disclosed |
| US-20100216779-A1 | Imidazopyridine Kinase Inhibitors | GLAXOSMITHKLINE LLC | 2010-08-26 | — | — | US | disclosed |
| EP-2162454-A1 | IMIDAZOPYRIDINE KINASE INHIBITORS | GlaxoSmithKline LLC (US) | 2010-03-17 | — | — | EP | disclosed |
| WO-2008150799-A1 | IMIDAZOPYRIDINE KINASE INHIBITORS | SMITHKLINE BEECHAM CORPORATION (US) | 2008-12-11 | — | — | WO | disclosed |
| US-20080300242-A1 | Imidazopyridine Kinase Inhibitors | GLAXOSMITHKLINE LLC | 2008-12-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080300242-A1 | Imidazopyridine Kinase Inhibitors | ABL1, MAP3K19, MAP3K5 | RAB9A 1901/4885KMT2A 800/4885MEN1 2992/4885 |
| US-20100216779-A1 | Imidazopyridine Kinase Inhibitors | ABL1, MAP3K19, MAP3K5 | RAB9A 1901/4885KMT2A 800/4885MEN1 2992/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.